公开(公告)号：US07892760B2

公开(公告)日：2011-02-22

申请号：US12273994

申请日：2008-11-19

Applicant: Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

Inventor： Charles Birse ,  Marcia Lewis ,  Steve Ruben ,  Mehdi Mesri

IPC: G01N33/53

CPC classification number: G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

Abstract translation: 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂）及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。

公开(公告)号：US20120076725A1

公开(公告)日：2012-03-29

申请号：US13005031

申请日：2011-01-12

Applicant: Charles BIRSE ,  Marcia LEWIS ,  Steve RUBEN ,  Mehdi MESRI

Inventor： Charles BIRSE ,  Marcia LEWIS ,  Steve RUBEN ,  Mehdi MESRI

IPC: G01N33/566 ,  A61P35/00 ,  A61K51/10 ,  C12Q1/68 ,  G01N21/64

CPC classification number: G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2333/8114 ,  G01N2333/96486 ,  G01N2800/56

Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.

Abstract translation: 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。

公开(公告)号：US20120177659A1

公开(公告)日：2012-07-12

申请号：US13339833

申请日：2011-12-29

Applicant: Steve RUBEN ,  Karen VAN ORDEN ,  Candy N. LEE ,  Tao HE ,  Mehdi MESRI ,  Elizabeth G. JOSELOFF ,  Paul MOORE ,  Katherine MCKINNON ,  Bruno DOMON

Inventor： Steve RUBEN ,  Karen VAN ORDEN ,  Candy N. LEE ,  Tao HE ,  Mehdi MESRI ,  Elizabeth G. JOSELOFF ,  Paul MOORE ,  Katherine MCKINNON ,  Bruno DOMON

IPC: A61K39/395 ,  C07K14/47 ,  C12N9/10 ,  C12N9/12 ,  C12N9/48 ,  C12N9/14 ,  A61K38/02 ,  A61K38/17 ,  A61K38/45 ,  A61K38/48 ,  A61K38/46 ,  C07H21/04 ,  C07H21/02 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C07K16/42 ,  C12N5/16 ,  C12N5/071 ,  C12N5/09 ,  G01N33/566 ,  C12Q1/68 ,  A61P35/00 ,  C12N5/10 ,  C12N1/21 ,  C12N1/19 ,  C07K14/705

CPC classification number: G01N33/57484 ,  A61K38/00 ,  A61K47/6843 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/18 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C12N15/113 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/6893 ,  G01N2500/10 ,  Y10T436/143333

Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.

Abstract translation: 提供了与健康细胞相比，用于诊断和治疗与疾病细胞中癌症相关靶（CAT）不同表达相关的疾病，特别是癌症的方法和组合物。 还提供了CAT的拮抗剂和激动剂，以及用于筛选在体内或体外调节CAT水平或活性的药剂的方法。

公开(公告)号：US20050084449A1

公开(公告)日：2005-04-21

申请号：US10805177

申请日：2004-03-19

Applicant: Gregory Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

Inventor： Gregory Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

IPC: A61K39/395 ,  A61K51/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/06 ,  G01N33/53

CPC classification number: C07K16/2803 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/50 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N2333/70503

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract translation: 本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体的用途。 特别地，提供针对抗原TIM-1的完全人单克隆抗体。 分离的多核苷酸序列编码和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：US20120251555A1

公开(公告)日：2012-10-04

申请号：US13305898

申请日：2011-11-29

Applicant: Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

Inventor： Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

IPC: C07K16/28 ,  C12N5/10 ,  A61P35/00 ,  A61K39/395 ,  G01N33/574 ,  G01N21/64 ,  C12N5/16 ,  C12N5/09

CPC classification number: C07K16/2803 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/50 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N2333/70503

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract translation: 本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体的用途。 特别地，提供针对抗原TIM-1的完全人单克隆抗体。 分离的多核苷酸序列编码和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：US08067544B2

公开(公告)日：2011-11-29

申请号：US10805177

申请日：2004-03-19

Applicant: Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

Inventor： Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

IPC: C07K16/00

CPC classification number: C07K16/2803 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/50 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N2333/70503

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract translation: 本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体的用途。 特别地，提供针对抗原TIM-1的完全人单克隆抗体。 分离的多核苷酸序列编码和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：US20110250204A1

公开(公告)日：2011-10-13

申请号：US12901254

申请日：2010-10-08

Applicant: Steve RUBEN ,  Paul A. MOORE ,  Tao HE ,  Candy N. LEE ,  Karen VAN ORDEN ,  Charles E. Birse ,  Mehdi Mesri ,  Elizabeth G. Joseloff

Inventor： Steve RUBEN ,  Paul A. MOORE ,  Tao HE ,  Candy N. LEE ,  Karen VAN ORDEN ,  Charles E. Birse ,  Mehdi Mesri ,  Elizabeth G. Joseloff

IPC: A61K39/395 ,  C07H21/02 ,  C07K16/00 ,  C07K16/18 ,  A61P35/00 ,  C12N5/071 ,  G01N33/53 ,  C12Q1/02 ,  A61K31/7088 ,  G01N33/68 ,  C07H21/04 ,  C12N5/16

CPC classification number: C07K16/3076 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/70546 ,  C07K14/70596 ,  C07K16/18 ,  C07K16/2839 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/303 ,  C07K16/40 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/734 ,  C12N9/18 ,  C12N9/6424 ,  C12N15/113 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y301/01 ,  C12Y304/21 ,  C12Y304/21109 ,  G01N33/57488 ,  G01N33/57492

Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Abstract translation: 提供用于评估，治疗和预防使用癌症相关靶（CAT）的疾病，特别是癌症的方法和组合物。 还提供了用于确定或预测这些疾病的治疗或使用CAT选择治疗的有效性的方法和组合物。 还提供了使用CAT调节细胞功能的方法和组合物。 还提供了调节CAT（例如拮抗剂或激动剂）如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义试剂）的组合物及其药物组合物。 进一步提供了筛选调节CAT的试剂的方法，以及通过这些筛选方法鉴定的试剂。

公开(公告)号：US20050197292A1

公开(公告)日：2005-09-08

申请号：US11047207

申请日：2005-01-31

Applicant: Glennda Smithson ,  Mehdi Mesri ,  Gary Starling

Inventor： Glennda Smithson ,  Mehdi Mesri ,  Gary Starling

IPC: A61K38/17 ,  C07K14/72

CPC classification number: A61K38/16 ,  Y02A50/463

Abstract: The present invention relates to compositions and methods for preventing and/or treating inflammatory and autoimmune diseases. More particularly, the present invention relates to compositions comprising a CG57008 protein, fragment, derivative, variant, homolog, or analog thereof, and their uses in preventing and/or treating T-cell mediated diseases.

Abstract translation: 本发明涉及用于预防和/或治疗炎性和自身免疫性疾病的组合物和方法。 更具体地，本发明涉及包含CG57008蛋白，其片段，衍生物，变体，同源物或类似物的组合物及其在预防和/或治疗T细胞介导的疾病中的用途。

公开(公告)号：US20050014687A1

公开(公告)日：2005-01-20

申请号：US10391939

申请日：2003-03-19

Applicant: David Anderson ,  Loic Giot ,  Xiaojia Guo ,  Denise Lepley ,  Mehdi Mesri ,  Chean Ooi ,  Luca Rastelli ,  Daniel Rieger ,  Glennda Smithson ,  Gary Starling ,  Kam-Fai Tse

Inventor： David Anderson ,  Loic Giot ,  Xiaojia Guo ,  Denise Lepley ,  Mehdi Mesri ,  Chean Ooi ,  Luca Rastelli ,  Daniel Rieger ,  Glennda Smithson ,  Gary Starling ,  Kam-Fai Tse

IPC: G01N33/50 ,  A61K38/00 ,  A61K38/17 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/18 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/53 ,  G01N33/567 ,  G01N33/68

CPC classification number: C07K14/47 ,  G01N33/6893 ,  G01N2800/042

Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

公开(公告)号：US09580503B2

公开(公告)日：2017-02-28

申请号：US13305898

申请日：2011-11-29

Applicant: Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

Inventor： Gregory M. Landes ,  Francine Chen ,  Binyam Bezabeh ,  Ian Foltz ,  Kam Fai Tse ,  Michael Jeffers ,  Mehdi Mesri ,  Gary Starling ,  Peter Mezes ,  Nikolia Khramtsov

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/50 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N2333/70503

Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract translation: 本文描述的发明涉及针对抗原TIM-1的抗体和这种抗体的用途。 特别地，提供针对抗原TIM-1的完全人单克隆抗体。 分离的多核苷酸序列编码和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区（FR）和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是FR1至FR4 或CDR1至CDR3。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。